BCRX Stock Cash Flow Statements

BioCryst Pharmaceuticals Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

BioCryst Pharmaceuticals Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31

cash flows from operating activities:
net income	5,085,000	32,000	-26,795,000	-14,033,000	-12,674,000	-35,379,000	-61,731,000	-36,149,000	-75,326,000	-53,333,000	-71,541,000	-42,520,000	-58,859,000	-74,196,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	329,000	331,000	309,000	311,000	320,000	306,000	423,000	420,000	407,000	405,000	396,000	389,000	335,000	317,000
inventory obsolescence	817,000	209,000	-11,000	1,360,000			186,000	-2,000	2,000	236,000
stock-based compensation expense	21,304,000	21,368,000	21,339,000	17,249,000	13,173,000	13,652,000	16,488,000	12,279,000	12,841,000	14,007,000	15,282,000	9,951,000	9,867,000	9,601,000
payment of pharmakon pik interest
non-cash interest expense on royalty financing obligations
non-cash interest expense on secured term loan and amortization of debt issuance costs
amortization of discount on investments	-1,150,000	-1,383,000
loss on extinguishment of debt								0
changes in operating assets and liabilities:
increase in receivables
decrease (increase) in inventory
decrease in prepaid expenses and other assets
decrease in royalty financing obligations
decrease in accounts payable and accrued expenses
net cash from operating activities	41,302,000	-27,517,000	-5,213,000	8,245,000	-1,368,000	-53,684,000	-8,918,000	-19,897,000	-18,814,000	-47,512,000	-23,849,000	-32,444,000	-27,757,000	-77,800,000
capex	-179,000	-143,000	-675,000	-59,000	-155,000	-235,000	-554,000	-987,000	-467,000	-160,000	0	-175,000	-244,000	-406,000
free cash flows	41,123,000	-27,660,000	-5,888,000	8,186,000	-1,523,000	-53,919,000	-9,472,000	-20,884,000	-19,281,000	-47,672,000	-23,849,000	-32,619,000	-28,001,000	-78,206,000
cash flows from investing activities:
acquisitions of property and equipment	-179,000	-143,000	-675,000	-59,000	-155,000	-235,000	-554,000	-987,000	-467,000	-160,000		-175,000	-244,000	-406,000
purchases of investments	-29,341,000	-48,762,000
sales and maturities of investments					110,000,000	117,000,000	129,069,000	147,995,000	66,325,000	41,688,000	77,741,000	35,655,000
net cash from investing activities	29,127,000	27,095,000	17,797,000	8,489,000	-2,449,000	28,756,000	-28,473,000	23,119,000	-19,035,000	-107,109,000	77,215,000	-69,543,000	-97,438,000	-38,472,000
cash flows from financing activities:
net proceeds from common stock issued under stock-based compensation plans	3,421,000	2,390,000	-586,000	2,085,000	264,000	1,681,000	-178,000	1,487,000	1,954,000	5,077,000	4,199,000	3,253,000	147,000	7,356,000
common stock issued to directors in lieu of cash retainer	9,000	6,000	5,000	6,000
repayment of pharmakon term loan principal
prepayment premium and fees on pharmakon term loan
principal payments on royalty financing obligations
withholding taxes paid on stock-based awards	-866,000	-1,351,000	-3,084,000	-261,000	-1,840,000	-2,350,000
principal payments on finance lease liabilities	-536,000	-516,000	-356,000	-556,000	-402,000	-390,000
net cash from financing activities	-73,686,000	529,000	-4,021,000	1,274,000	-1,966,000	-1,048,000	-3,173,000	1,225,000	29,356,000	5,077,000	4,199,000	76,325,000	147,000	7,356,000
effect of exchange rates on cash, cash equivalents and restricted cash	1,359,000	451,000
decrease in cash, cash equivalents and restricted cash, including cash classified within current assets held for sale
less: net increase in cash and cash equivalents classified within current assets held for sale
net decrease in cash, and cash equivalents, and restricted cash
cash, cash equivalents and restricted cash:
beginning of period	0	106,323,000
end of period	-16,956,000	106,881,000
reconciliation of cash, cash equivalents and restricted cash:
cash and cash equivalents	-17,157,000	105,190,000
restricted cash	201,000	291,000
restricted cash in other assets	0	1,400,000
total cash, cash equivalents and restricted cash	-16,956,000	106,881,000
non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs		14,058,000	14,036,000	14,530,000	19,601,000	19,440,000	19,517,000	22,351,000	23,719,000	20,216,000	43,799,000	18,394,000	17,722,000	19,003,000
receivables		-13,987,000	-7,296,000	-3,317,000	-8,246,000	-3,839,000	-2,970,000	3,843,000	-8,987,000	2,019,000	-7,643,000	-1,484,000	-5,295,000	-7,048,000
inventory		-870,000	-2,163,000	-1,520,000	739,000	-1,220,000	907,000	-3,386,000	898,000	131,000	-1,160,000	-3,674,000	-7,235,000	-354,000
prepaid expenses and other assets		-132,000	574,000	-1,466,000	1,745,000	1,106,000	710,000	-6,046,000	1,063,000	-2,547,000	-1,451,000	-82,000	1,270,000	-2,320,000
accounts payable and accrued expenses		-47,143,000	-2,446,000	-2,830,000	-12,534,000	-44,569,000	19,872,000	-9,264,000	-188,000	-27,226,000	5,279,000	-19,176,000	14,445,000	-22,908,000
maturities of investments		76,000,000	58,000,000
increase in cash, cash equivalents and restricted cash		558,000
supplemental cash flow disclosure:
cash paid for interest		9,153,000	10,141,000	10,201,000	5,054,000	4,987,000
cash paid for taxes		1,000	378,000	360,000	679,000	186,000
taxes withheld on stock-based awards included in accrued expenses		276,000	513,000	56,000	-1,657,000	1,846,000
amortization of premium (discount) on investments
loss on impairment
deferred revenue							-419,000	-1,346,000	570,000	-35,000	-438,000	143,000	111,000	75,000
net proceeds from secured term loans							0
repayment of athyrium secured term loans principal							0	0
prepayment and repayment fees on athyrium secured term loans							0	0
payment of debt issuance costs on pharmakon tranche a term loan							0	-262,000
decrease in cash, cash equivalents and restricted cash			7,259,000	18,859,000	-5,926,000	-26,316,000		4,700,000	-8,810,000	-149,640,000		-25,676,000	-124,839,000	-108,876,000
beginning of year
end of year
amortization of premium/discount on investments				-2,039,000	-3,493,000	-3,181,000	-3,449,000	-2,597,000	-2,832,000	-1,385,000	-959,000	-730,000	-118,000	30,000
purchase of investments				-26,932,000	-112,294,000	-88,009,000		-123,889,000	-84,893,000	-148,637,000		-105,023,000	-101,194,000	-38,066,000
net proceeds from pharmakon tranche a term loan
effect of exchange rate on cash, cash equivalents, and restricted cash				851,000	-143,000	-340,000		253,000	-317,000	-96,000		-14,000	209,000	40,000
cash, cash equivalents and restricted cash at beginning of period				0	0	112,447,000		0	0	306,239,000		0	0	507,734,000
cash, cash equivalents and restricted cash at end of period				18,859,000	-5,926,000	86,131,000		4,700,000	-8,810,000	156,599,000		-25,676,000	-124,839,000	398,858,000
net proceeds from common stock issued to directors in lieu of cash retainer						11,000
gain on extinguishment of debt
interest payable
sale of common stock
net proceeds from royalty financing liabilities
effects of exchange rates on cash, cash equivalents and restricted cash
cash, cash equivalents and restricted cash at beginning of year
cash, cash equivalents and restricted cash at end of year
inventory obsolescence expense
change in fair value of foreign currency derivative
(gain) loss on extinguishment of debt
acquisition of property and equipment
sale of pre-funded warrants
proceeds from additional credit facility
payment of senior credit facility
net proceeds from secured term loan
net proceeds from royalty financing obligations
realized gain on investments
non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs
proceeds from senior credit facility
cash flows from operating activities
non-cash interest expense on royalty financing obligation
non-cash paid in-kind interest on secured term loan
amortization of debt issuance costs
cash flows from investing activities
cash flows from financing activities
effect of exchange rate on cash and cash equivalents
operating activities
investing activities
financing activities
accounts payable, accrued expenses and other liabilities
operating activities:
gain on disposal of property and equipment
net cash from operating activities:
investing activities:
net cash from investing activities:
financing activities:
net proceeds from royalty financing obligation
increase in lease financing obligation
net cash from financing activities:
net cash provided by financing activities
proceeds from sale of property and equipment
deferred collaboration expense
decrease in lease financing obligation
depreciation, amortization, and impairment
(gain) loss on disposal of property and equipment
change in restricted cash
increase in cash and cash equivalents
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
loss on disposal of property and equipment
payment of foreign currency derivative collateral
cash and cash equivalents at beginning of period
cash and cash equivalents at end of period
net cash provided (used) in investing activities:
decrease in cash and cash equivalents
exercise of stock options
employee stock purchase plan sales
receipt of foreign currency derivative collateral
acquisitions of furniture and equipment
gain on disposal of furniture and equipment
acquisition of furniture and equipment
proceeds from sale of furniture and equipment
receipt (payment) of foreign currency derivative collateral
deferred collaboration revenue
(payment) receipt of foreign currency derivative collateral
receivables from collaborations
proceeds from sale furniture and equipment
purchases of treasury stock
issuance of non-recourse notes payable
interest reserve
prepaid expenses and other current assets
inventories
deferred rent
purchases of marketable securities
sales and maturities of marketable securities
common stock issuance costs
debt issuance costs
sale of common stock, net of issuance costs
depreciation, amortization and impairment
purchases of patents and licenses
maturities of marketable securities
cash and equivalents at beginning of year
depreciation and amortization of furniture and equipment
impairment of furniture and equipment
amortization of patents and licenses
impairment of patents and licenses
accounts payable
accrued expenses
accrued vacation
receivable from collaboration
non-monetary compensation
changes in operating assets and liabilities
purchases of furniture and equipment
proceeds from sale of common stock
non-monetary compensation cost
deferred expense
purchase of marketable securities
principal payments of debt and capital lease obligations
employee stock purchase plan stock sales

We provide you with 20 years of cash flow statements for BioCryst Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BioCryst Pharmaceuticals stock. Explore the full financial landscape of BioCryst Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about BioCryst Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.